Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCHE | P06276 | 5/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 2/20 | 0.40 |
| ▸ | IGF1R | P08069 | 2/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17471702 | 0.98 | BCHE (0.42) | BCHECA2CYP4F2CYP4A11ACHE | |
| SCHEMBL17471720 | 0.93 | CYP4A11 (0.41) | BCHECA2CYP4F2CYP4A11IGF1R | |
| SCHEMBL17471715 | 0.85 | KDM4E (0.47) | CA2CYP4F2CYP4A11ALDH1A1S1PR1 | |
| SCHEMBL17471730 | 0.84 | BCHE (0.42) | BCHECA2CYP4F2CYP4A11ACHE | |
| SCHEMBL17471727 | 0.79 | SKP2 (0.47) | BCHECA2CYP4F2CYP4A11ACHE | |
| SCHEMBL2208303 | 0.77 | S1PR1 (0.41) | CA2CYP4F2CYP4A11ACHES1PR1 | |
| SCHEMBL31689465 | 0.77 | S1PR1 (0.41) | CA2CYP4F2CYP4A11ACHES1PR1 | |
| SCHEMBL16502363 | 0.76 | HTR2A (0.47) | IGF1RALOX15 | |
| SCHEMBL11639232 | 0.76 | BCHE (0.45) | BCHECA2CYP4F2CYP4A11ACHE | |
| SCHEMBL17471707 | 0.76 | CYP1A2 (0.53) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160024098-A1 | HYBRID NECROPTOSIS INHIBITORS | RIPK3, RIPK1, RIPK4 | BCHE 4764/4885CA2 2954/4885CYP4F2 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.